A Phase 3 clinical trial for Pro-ocular patients suffering from ocular Graft-versus-Host Disease (oGvHD)

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 26 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Mar 2025 New trial record
18 Mar 2025 According to a Signal12 media release, company today announced alignment of its Phase 3 clinical trial strategy for Pro-ocular, after receiving positive feedback about trial design from US Food and Drug Administration (FDA). This key regulatory milestone, achieved following a highly productive Type C meeting, sets the stage for Signal12's transformative Phase 3 clinical research in an area of high unmet medical need. Company looks forward to initiating Phase 3 trial as soon as possibl

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com